What is Mapi Pharma?
Headquartered in Ness Ziona, Israel, Mapi Pharma operates as a clinical-stage pharmaceutical enterprise specializing in the development of innovative long-acting depot injectable treatments. By leveraging complex active pharmaceutical ingredients, the company addresses significant therapeutic gaps in chronic conditions such as multiple sclerosis, neuropathic pain, and schizophrenia. The firm distinguishes itself through fully integrated GMP manufacturing capabilities, which provide a robust foundation for scaling its lead product, Glatiramer Acetate Depot, alongside its broader portfolio of extended-release formulations. This operational maturity allows Mapi Pharma to maintain rigorous quality standards while navigating the complexities of international regulatory pathways.
How much funding has Mapi Pharma raised?
Mapi Pharma has raised a total of $10M across 1 funding round:
Share Placement
$10M
Share Placement (2015): $10M with participation from Shavit Capital
Key Investors in Mapi Pharma
Shavit Capital
Shavit Capital is an investment practice founded in 2008 that specializes in late-stage investments in Israeli and Israeli-related companies. With over $500 million under management across five private equity funds, the firm focuses on companies with proven technologies, products, markets, and strong management teams.
What's next for Mapi Pharma?
The infusion of capital is expected to catalyze the next phase of Mapi Pharma's growth, specifically targeting the advancement of its late-stage clinical trials and the optimization of its manufacturing infrastructure. As the company transitions toward commercialization, the strategic focus will likely shift toward securing global partnerships and navigating the regulatory requirements for its flagship assets. By prioritizing the development of high-barrier-to-entry pharmaceutical products, Mapi Pharma aims to capture significant market share in the neurology and psychiatry sectors, ultimately enhancing patient outcomes through improved treatment adherence and efficacy.
See full Mapi Pharma company page
